CITIUS ONCOLOGY, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 11 COMMERCE DRIVE, CRANFORD, NJ, 07016
Mailing Address 11 COMMERCE DRIVE, CRANFORD, NJ, 07016
Phone (908) 967-6677
Fiscal Year End 0930
EIN 994362660
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-Q Quarterly financial report | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 10-K Annual financial report | December 23, 2025 | View on SEC |
| 4/A Insider transaction amendment | December 22, 2025 | View on SEC |
| 4/A Insider transaction amendment | December 22, 2025 | View on SEC |
| 4/A Insider transaction amendment | December 22, 2025 | View on SEC |
| 4/A Insider transaction amendment | December 22, 2025 | View on SEC |
| 4/A Insider transaction amendment | December 22, 2025 | View on SEC |
Annual Reports
10-K December 23, 2025
- Citius Oncology, Inc. became a publicly-traded company via a reverse merger in August 2024, remaining majority-owned by Citius Pharmaceuticals, Inc.
- The company's primary objective is to commercialize its product, LYMPHIR™ (denileukin diftitox).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.